← 產業報告目錄

Targeted Protein Degradation Market by Type [PROTACs (Vepdegestrant, Bavdegalutamide), SERDs (Elacestrant), Molecular Glues (Mezigdomide), LDD, LYTAC/ATAC], Indication (Oncology, Inflammatory), Formulation (Oral), End User - Global Forecast to 2035

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-08-23頁數 354報告編號 PH9483

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global targeted protein degradation market is projected to reach USD 9.85 billion by 2035 from an estimated USD 0.48 billion in 2025, at a CAGR of 35.4% from 2025 to 2035. The expansion of the targeted protein degradation market has been predominantly fueled by Capital inflows & big-pharma tie-ups, and multi-indication expansion. However, CMC & scale-up complexity for heterobifunctional and IP disputes are expected to restrain market growth. The oncology segment reported the highest CAGR in the therapeutic indications segment in 2024. Based on therapeutic indications, the market is categorized into oncology, inflammatory diseases, and other therapeutic indications. Oncology is projected to exhibit the highest CAGR in the targeted protein degradation Market among all therapeutic indication segments. This rapid growth is driven by the increasing global burden of cancer and the urgent need for therapies that can target disease-causing proteins once considered undruggable. TPD technologies, including PROTACs and molecular glue degraders, offer a revolutionary approach by degrading, rather than inhibiting key oncogenic proteins, leading to more complete and durable therapeutic responses. Several biotech and pharmaceutical companies are advancing TPD candidates specifically for oncology indications, including prostate, breast, lung, hematologic, and solid tumors. Industry leaders, such as Arvinas, Kymera Therapeutics, Nurix Therapeutics, and C4 Therapeutics, are developing clinical-stage degraders targeting critical cancer-related proteins like AR, ER, STAT3, and BTK. Additionally, big pharma partnerships and increasing regulatory support are accelerating development timelines. With a growing focus on precision medicine, rising cancer incidence, and limitations of existing therapies, the oncology segment is poised to dominate the targeted protein degradation market. Continued innovation in TPD design, biomarker integration, and combination therapies will further drive growth and solidify oncology’s role as the most dynamic and promising application area in this market. The homecare settings segment registered the highest CAGR in the targeted protein degradation market by end user. The targeted protein degradation market is segmented by end users into hospitals & specialty clinics, long-term care facilities, and home care settings. In 2024, the home care settings segment emerged as the fastest-growing end-user segment in the targeted protein degraders (TPD) market, driven by the growing demand for patient-centric, convenient, and cost-effective treatment options. One of the key factors contributing to this trend is the increasing development of oral TPD formulations, which allow patients to manage complex conditions like cancer and autoimmune diseases from the comfort of their homes. Unlike traditional biologics requiring hospital administration, oral degraders enable safe, effective treatment without the need for frequent clinic visits, significantly improving patient compliance and quality of life. The shift toward home-based care is further supported by the integration of digital health technologies, including remote patient monitoring and telehealth platforms, which allow physicians to track treatment response and manage side effects in real time. Healthcare systems are actively encouraging homecare models to reduce hospital burden and control treatment costs. As more targeted protein degraders progress through late-stage clinical development and gain regulatory approval, the dominance of home care settings is expected to strengthen. With their convenience, scalability, and alignment with modern healthcare delivery models, home care environments represent a vital and expanding channel for TPD therapies in the evolving treatment landscape. North America accounted for the largest share in the global targeted protein degradation market from 2025 to 2030. North America accounted for the largest share in the targeted protein degradation market, driven by a strong foundation in biotechnology innovation, a favorable regulatory landscape, and significant investment activity. The region is home to several pioneering TPD companies, including Arvinas, Kymera Therapeutics, Nurix Therapeutics, and C4 Therapeutics, which are advancing cutting-edge degrader technologies into clinical development. In addition, major pharmaceutical firms such as Bristol Myers Squibb and Pfizer are actively expanding their TPD pipelines through collaborations and internal R&D. The region benefits from a mature healthcare infrastructure, access to top-tier academic research institutions, and early adoption of novel therapeutic modalities. The US Food and Drug Administration (FDA) has shown increasing recognition of TPD-based therapies, granting designations that facilitate faster development and approval. Furthermore, the growing emphasis on oral and home-based treatments aligns well with healthcare delivery models in North America. These factors collectively position North America as a key driver of innovation, commercialization, and clinical advancement in the global TPD market, making it the fastest-growing regional segment. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side- 70% and Demand Side- 30% • By Designation: Managers- 45%, CXO and Directors- 30%, and Executives- 25% • By Region: North America- 30%, Europe- 30%, Asia Pacific- 30%, Latin America- 5%, and the Middle East & Africa- 5% Key Companies Key players in the targeted protein degradation market include Bristol Myers Squibb (US), Arvinas (US), BeiGene (US), Nurix (US), Kymera (US), C4 Therapeutics (US), Stemline Therapeutics (US), AstraZeneca (UK), F. Hoffmann-La Roche Ltd (Switzerland), Bayer (Vividion) (Germany), Captor Therapeutics (Poland), Ranok Therapeutics (US), Pfizer (US), Novartis (Switzerland), and Foghorn Therapeutics (US). Research Coverage This research report categorizes the targeted protein degradation market, by type [molecular glue (mezigdomide, Iberdomide), SERDs (Elacestrant, Giredestrant, Camizestrant), PROTAC (Vepdegestrant, Bavdegalutamide, BGB-16673, NX-5948, KT-474), LDD/BiDAC, LYTAC/ATAC, Autophhagy-targeting chimeras] therapeutic indication (oncology, inflammatory diseases, and others), Formulation (oral formulationsand injections), end user (hospitals & speciality clinics, long-term care facility and home care settings) and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the targeted protein degradation market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations, acquisitions, and recent developments associated with the targeted protein degradation market. Reasons to buy this report The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the overall targeted protein degradation market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges. The report provides insights on the following pointers: • Analysis of key drivers (Increasing first-In-class approvals with priority/FT designations, expanding multi-indication use, increasing capital inflows and big-pharma collaborations, and technological advancements in degrader design and discovery) restraints (CMC and scale-up complexity for heterobifunctionals, off-target toxicity and cytokine storms in first-gen PROTACs, and IP disputes), opportunities (Growing adoption of CNS and immunology degraders in clinics, development of next-gen ligases with tissue-selective expression, and increasing NDA filing for innovative degraders), and challenges (Limited ligase expression and strict regulatory guidelines) influencing the growth of the market. • Service Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the targeted protein degradation market • Market Development: Comprehensive information about lucrative markets across varied regions • Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the targeted protein degradation market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the targeted protein degradation market.
目錄 Table of Contents
1 INTRODUCTION 36 1.1 STUDY OBJECTIVES 36 1.2 MARKET DEFINITION 36 1.3 STUDY SCOPE 37 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 37 1.3.2 INCLUSIONS AND EXCLUSIONS 38 1.3.3 YEARS CONSIDERED 38 1.4 CURRENCY CONSIDERED 39 1.5 STAKEHOLDERS 39 2 RESEARCH METHODOLOGY 40 2.1 RESEARCH DATA 40 2.1.1 SECONDARY DATA 41 2.1.1.1 Objectives of secondary research 41 2.1.1.2 Key data from secondary sources 42 2.1.2 PRIMARY DATA 42 2.1.2.1 Breakdown of primaries (supply- and demand-side participants) 43 2.1.2.2 Key objectives of primary research 43 2.2 MARKET SIZE ESTIMATION 44 2.2.1 GLOBAL MARKET SIZE ESTIMATION 44 2.2.1.1 Company revenue analysis (Bottom-up approach) 44 2.2.1.2 Revenue share analysis 45 2.2.1.3 MnM repository analysis 46 2.2.1.4 Primary interviews 46 2.2.2 INSIGHTS FROM PRIMARY EXPERTS 47 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 47 2.3 GROWTH RATE PROJECTIONS 49 2.4 DATA TRIANGULATION 50 2.5 RESEARCH ASSUMPTIONS 51 2.6 RESEARCH LIMITATIONS 52 2.7 RISK ANALYSIS 52 3 EXECUTIVE SUMMARY 53 3.1 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS 53 3.1.1 BIOTECH STARTUPS AND INNOVATIVE COMPANIES 53 3.1.2 ESTABLISHED MARKET LEADERS 53 3.1.3 CDMOS AND CROS 54   4 PREMIUM INSIGHTS 59 4.1 NOVEL TARGETED PROTEIN DEGRADERS MARKET OVERVIEW 59 4.2 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE AND COUNTRY, 2030 60 4.3 NOVEL TARGETED PROTEIN DEGRADERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 61 4.4 NOVEL TARGETED PROTEIN DEGRADERS MARKET: EMERGING VS. DEVELOPED MARKETS 62 5 MARKET OVERVIEW 63 5.1 INTRODUCTION 63 5.2 MARKET DYNAMICS 63 5.2.1 DRIVERS 65 5.2.1.1 Growing approvals and favorable regulatory environment 65 5.2.1.2 Multi-indication expansion 65 5.2.1.3 Capital inflows and big pharma tie-ups 66 5.2.1.4 Technological advancements in design and discovery 67 5.2.2 RESTRAINTS 67 5.2.2.1 Cost and scalability issues 67 5.2.2.2 Safety-related concerns 68 5.2.2.3 Intellectual property disputes 69 5.2.3 OPPORTUNITIES 69 5.2.3.1 Advancements in medicinal chemistry 69 5.2.3.2 Development of next-gen ligases with tissue-selective expressions 70 5.2.3.3 Increasing NDA filings for innovative degraders 70 5.2.4 CHALLENGES 71 5.2.4.1 Limited ligase expression in tissues 71 5.2.4.2 Strict regulatory guidelines 71 5.3 TECHNOLOGY ANALYSIS 72 5.3.1 KEY TECHNOLOGIES 72 5.3.1.1 PROTACS (hetero-bifunctional) 72 5.3.1.2 Molecular glues/CELMODS 72 5.3.2 COMPLEMENTARY TECHNOLOGIES 73 5.3.2.1 Next-gen E3-ligase binder discovery 73 5.3.2.2 Nanoparticle/LNP delivery of degraders 73 5.3.3 ADJACENT TECHNOLOGIES 73 5.3.3.1 Antibody-drug conjugates (ADCs) 73 5.3.3.2 GENE editing/siRNA 73 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES 74 5.5 PRICING ANALYSIS 75 5.5.1 QUALITATIVE PRICING INSIGHTS FOR ELACESTRANT (ORSERDU), 2024 75 5.5.2 QUALITATIVE PRICING INSIGHTS FOR UPCOMING NOVEL TARGETED PROTEIN DEGRADERS 75 5.6 REIMBURSEMENT SCENARIO FOR ELACESTRANT (ORSERDU) 76 5.6.1 US 76 5.6.2 EUROPE 76 5.7 VALUE CHAIN ANALYSIS 77 5.8 ECOSYSTEM ANALYSIS 78 5.9 PATENT ANALYSIS 80 5.10 PIPELINE ANALYSIS 83 5.11 REGULATORY ANALYSIS 84 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION 84 5.11.2 REGULATORY FRAMEWORK 86 5.12 KEY CONFERENCES AND EVENTS, 2025–2026 88 5.13 PORTER’S FIVE FORCES ANALYSIS 89 5.13.1 THREAT OF NEW ENTRANTS 90 5.13.2 THREAT OF SUBSTITUTES 90 5.13.3 BARGAINING POWER OF SUPPLIERS 90 5.13.4 BARGAINING POWER OF BUYERS 90 5.13.5 INTENSITY OF COMPETITIVE RIVALRY 91 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 91 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 91 5.14.2 KEY BUYING CRITERIA 93 5.15 INVESTMENT AND FUNDING SCENARIO 94 5.16 IMPACT OF AI/GEN AI ON NOVEL TARGETED PROTEIN DEGRADERS MARKET 95 5.17 IMPACT OF 2025 US TARIFFS ON NOVEL TARGETED PROTEIN DEGRADERS MARKET 96 5.17.1 INTRODUCTION 96 5.17.2 KEY TARIFF RATES 97 5.17.3 PRICE IMPACT ANALYSIS 97 5.17.4 IMPACT ON COUNTRY/REGION 97 5.17.4.1 North America 97 5.17.4.1.1 US 97 5.17.4.2 Europe 98 5.17.4.3 Asia Pacific 98 5.17.5 IMPACT ON END-USE INDUSTRIES 98 6 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE 99 6.1 INTRODUCTION 100 6.2 MOLECULAR GLUE 100 6.2.1 MEZIGDOMIDE (CC-92480) 104 6.2.1.1 Stronger cereblon binding and deeper substrate degradation to spur growth 104 6.2.2 IBERDOMIDE (CC-220) 107 6.2.2.1 Rising incidence of autoimmune diseases and cancer to boost market 107 6.3 SERDS 110 6.3.1 ELACESTRANT 113 6.3.1.1 Increasing approvals to contribute to growth 113 6.3.2 GIREDESTRANT (GDC9545) 116 6.3.2.1 Growing prevalence of breast cancer to drive market 116 6.3.3 CAMIZESTRANT (AZD9833) 119 6.3.3.1 High potency and strong receptor degradation to bolster growth 119 6.4 PROTAC 122 6.4.1 VEPDEGESTRANT (ARV-471) 126 6.4.1.1 Reliable systemic exposure and enhanced tumor targeting to support growth 126 6.4.2 LUXDEGALUTAMIDE 129 6.4.2.1 Favorable safety profile and early signals of efficacy to stimulate growth 129 6.4.3 BGB-16673 132 6.4.3.1 Higher efficacy and preference for oral formulation to aid growth 132 6.4.4 NX-5948 135 6.4.4.1 Advancements in next-gen oral BTK degraders targeting refractory B-cell malignancies to drive market 135 6.4.5 KT‑474 137 6.4.5.1 Rising importance in treating autoimmune and inflammatory diseases to aid growth 137 6.5 LDD/BIDAC 139 6.5.1 INCREASING USE OF LDD IN TUMOR-SPECIFIC DEGRADATION, HEMATOLOGIC CANCERS, AND IMMUNE MODULATION TO FUEL MARKET 139 6.6 LYTAC/ATAC 142 6.6.1 GROWING FOCUS ON CANCER IMMUNOTHERAPY TO DRIVE MARKET 142 6.7 AUTAC/ATTEC 144 6.7.1 GROWING USE OF AUTAC IN TREATING METABOLIC DISEASES AND RARE LYSOSOMAL STORAGE CONDITIONS TO BOOST MARKET 144 7 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION 147 7.1 INTRODUCTION 148 7.2 ONCOLOGY 148 7.2.1 HIGH PREVALENCE OF MALIGNANCIES AND UNMET NEED FOR DURABLE THERAPIES TO PROMOTE GROWTH 148 7.3 INFLAMMATORY DISEASES 152 7.3.1 CHANGES IN LIFESTYLES AND ENVIRONMENTAL CONDITIONS TO AUGMENT GROWTH 152 7.4 OTHER DISEASES 154   8 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION 157 8.1 INTRODUCTION 158 8.2 ORAL FORMULATIONS 158 8.2.1 TABLETS 162 8.2.1.1 Manufacturing scalability, stability, and patient convenience to aid growth 162 8.2.2 CAPSULES 165 8.2.2.1 Higher flexibility, faster development timelines, and enhanced bioavailability to foster growth 165 8.3 INJECTIONS 168 8.3.1 ESSENTIAL ROLE IN RAPID AND TARGETED DELIVERY OF SYSTEMIC TARGETED PROTEIN DEGRADERS TO BOOST MARKET 168 9 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER 171 9.1 INTRODUCTION 172 9.2 HOSPITALS & SPECIALTY CLINICS 172 9.2.1 ROBUST INFRASTRUCTURE AND MULTI-DISCIPLINARY CARE TEAMS TO EXPEDITE GROWTH 172 9.3 LONG-TERM CARE FACILITIES 176 9.3.1 INCREASING FOCUS ON QUALITY OF LIFE TO CONTRIBUTE TO GROWTH 176 9.4 HOME CARE SETTINGS 179 9.4.1 GROWING FOCUS ON CHRONIC DISEASE MANAGEMENT TO DRIVE MARKET 179 10 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY REGION 182 10.1 INTRODUCTION 183 10.2 NORTH AMERICA 183 10.2.1 MACROECONOMIC ANALYSIS FOR NORTH AMERICA 184 10.2.2 US 189 10.2.2.1 Strong clinical pipeline and regulatory support to contribute to growth 189 10.2.3 CANADA 192 10.2.3.1 Favorable government initiatives to support growth 192 10.3 EUROPE 195 10.3.1 MACROECONOMIC ANALYSIS FOR EUROPE 196 10.3.2 GERMANY 200 10.3.2.1 Strong industry-academia partnership to foster growth 200 10.3.3 UK 203 10.3.3.1 Presence of leading academic institutions and translational research hubs to aid growth 203 10.3.4 FRANCE 206 10.3.4.1 Presence of leading biotechnology and diagnostic companies to spur growth 206 10.3.5 ITALY 209 10.3.5.1 Increasing innovations in PROTAC technology to promote growth 209 10.3.6 SPAIN 213 10.3.6.1 Robust academic network to contribute to growth 213 10.3.7 REST OF EUROPE 215 10.4 ASIA PACIFIC 219 10.4.1 MACROECONOMIC ANALYSIS FOR ASIA PACIFIC 219 10.4.2 CHINA 224 10.4.2.1 Surge in clinical trial activities to spur growth 224 10.4.3 JAPAN 227 10.4.3.1 Large geriatric population to contribute to growth 227 10.4.4 INDIA 230 10.4.4.1 Expanding contract development and manufacturing organization infrastructure to fuel market 230 10.4.5 SOUTH KOREA 233 10.4.5.1 Rapidly expanding pharmaceutical manufacturing infrastructure to propel market 233 10.4.6 AUSTRALIA 236 10.4.6.1 Streamlined clinical trial environment to accelerate growth 236 10.4.7 REST OF ASIA PACIFIC 239 10.5 LATIN AMERICA 243 10.5.1 MACROECONOMIC ANALYSIS FOR LATIN AMERICA 243 10.5.2 BRAZIL 247 10.5.2.1 Regulatory evolution supporting trial acceleration to drive market 247 10.5.3 MEXICO 250 10.5.3.1 Rising demand for novel therapeutics for chronic disease treatment to support growth 250 10.5.4 REST OF LATIN AMERICA 253 10.6 MIDDLE EAST & AFRICA 257 10.6.1 MACROECONOMIC ANALYSIS FOR MIDDLE EAST & AFRICA 257 10.6.2 GCC COUNTRIES 261 10.6.2.1 Saudi Arabia 265 10.6.2.1.1 Growing focus on life sciences sector to boost market 265 10.6.2.2 UAE 268 10.6.2.2.1 Emerging biotechnology sector to intensify growth 268 10.6.2.3 REST OF GCC countries 271 10.6.3 REST OF MIDDLE EAST & AFRICA 274 11 COMPETITIVE LANDSCAPE 278 11.1 INTRODUCTION 278 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 278 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NOVEL TARGETED PROTEIN DEGRADERS MARKET 278 11.3 REVENUE ANALYSIS, 2028–2030 280 11.4 MARKET SHARE ANALYSIS, 2030 281 11.5 COMPANY VALUATION AND FINANCIAL METRICS 283 11.5.1 COMPANY VALUATION 283 11.5.2 FINANCIAL METRICS 283 11.6 BRAND/PRODUCT COMPARISON 284 11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 285 11.7.1 STARS 285 11.7.2 EMERGING LEADERS 285 11.7.3 PERVASIVE PLAYERS 285 11.7.4 PARTICIPANTS 285 11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 287 11.7.5.1 Company footprint 287 11.7.5.2 Region footprint 288 11.7.5.3 Degrader type footprint 289 11.7.5.4 Therapeutic indication footprint 290 11.7.5.5 Formulation footprint 291 11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 292 11.8.1 PROGRESSIVE COMPANIES 292 11.8.2 RESPONSIVE COMPANIES 292 11.8.3 DYNAMIC COMPANIES 292 11.8.4 STARTING BLOCKS 292 11.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 294 11.8.5.1 Detailed list of key startups/SMEs 294 11.8.5.2 Competitive benchmarking of key startups/SMEs 295 11.9 COMPETITIVE SCENARIO 296 11.9.1 PRODUCT LAUNCHES AND APPROVALS 296 11.9.2 DEALS 297 11.9.3 EXPANSIONS 298 12 COMPANY PROFILES 299 12.1 KEY PLAYERS 299 12.1.1 BRYSTOL-MYERS SQUIBB COMPANY 299 12.1.1.1 Business overview 299 12.1.1.2 Products offered 300 12.1.1.3 Recent developments 301 12.1.1.3.1 Deals 301 12.1.1.3.2 Expansions 302 12.1.1.4 MnM view 302 12.1.1.4.1 Key strengths 302 12.1.1.4.2 Strategic choices 302 12.1.1.4.3 Weaknesses and competitive threats 302   12.1.2 THE MENARINI GROUP 303 12.1.2.1 Business overview 303 12.1.2.2 Products offered 304 12.1.2.3 Recent developments 305 12.1.2.3.1 Product launches and approvals 305 12.1.2.4 MnM view 305 12.1.2.4.1 Key strengths 305 12.1.2.4.2 Strategic choices 305 12.1.2.4.3 Weaknesses and competitive threats 306 12.1.3 ARVINAS 307 12.1.3.1 Business overview 307 12.1.3.2 Products offered 308 12.1.3.3 Recent developments 308 12.1.3.3.1 Deals 308 12.1.3.4 MnM view 308 12.1.3.4.1 Key strengths 308 12.1.3.4.2 Strategic choices 309 12.1.3.4.3 Weaknesses and competitive threats 309 12.1.4 BEONE MEDICINES 310 12.1.4.1 Business overview 310 12.1.4.2 Products offered 311 12.1.4.3 Recent developments 311 12.1.4.3.1 Deals 311 12.1.5 NURIX THERAPEUTICS, INC. 312 12.1.5.1 Business overview 312 12.1.5.2 Products offered 313 12.1.5.3 Recent developments 313 12.1.5.3.1 Deals 313 12.1.6 KYMERA THERAPEUTICS, INC. 314 12.1.6.1 Business overview 314 12.1.6.2 Products offered 315 12.1.6.3 Recent developments 315 12.1.6.3.1 Deals 315 12.1.7 C4 THERAPEUTICS, INC. 316 12.1.7.1 Business overview 316 12.1.7.2 Products offered 317 12.1.7.3 Recent developments 317 12.1.7.3.1 Deals 317 12.1.8 ASTRAZENECA 318 12.1.8.1 Business overview 318 12.1.8.2 Products offered 319 12.1.8.3 Recent developments 320 12.1.8.3.1 Deals 320 12.1.8.3.2 Expansions 320 12.1.9 F. HOFFMANN-LA ROCHE LTD 321 12.1.9.1 Business overview 321 12.1.9.2 Products offered 322 12.1.9.3 Recent developments 323 12.1.9.3.1 Deals 323 12.1.10 BAYER AG 324 12.1.10.1 Business overview 324 12.1.10.2 Products offered 325 12.1.10.3 Recent developments 326 12.1.10.3.1 Deals 326 12.1.11 CAPTOR THERAPEUTICS 327 12.1.11.1 Business overview 327 12.1.11.2 Products offered 327 12.1.11.3 Recent developments 328 12.1.11.3.1 Deals 328 12.1.12 RANOK THERAPEUTICS CO. LTD. 329 12.1.12.1 Business overview 329 12.1.12.2 Products offered 329 12.1.12.3 Recent developments 329 12.1.12.3.1 Product launches and approvals 329 12.1.13 PFIZER INC. 330 12.1.13.1 Business overview 330 12.1.13.2 Products offered 331 12.1.13.3 Recent developments 332 12.1.13.3.1 Product launches and approvals 332 12.1.14 NOVARTIS AG 333 12.1.14.1 Business overview 333 12.1.14.2 Products offered 334 12.1.14.3 Recent developments 335 12.1.14.3.1 Deals 335 12.1.15 FOGHORN THERAPEUTICS 336 12.1.15.1 Business overview 336 12.1.15.2 Products offered 337 12.1.15.3 Recent developments 337 12.1.15.3.1 Deals 337   12.2 OTHER PLAYERS 338 12.2.1 MONTE ROSA THERAPEUTICS 338 12.2.2 BIOTHERYX, INC. 339 12.2.3 CULLGEN 340 12.2.4 NEOMORPH 340 12.2.5 LYCIA THERAPEUTICS 341 12.2.6 PHOTYS THERAPEUTICS 341 12.2.7 PLEXIUM, INC. 342 12.2.8 SEED THERAPEUTICS, INC. 343 12.2.9 AVILAR THERAPEUTICS, INC. 344 12.2.10 AUTOMERA 344 13 APPENDIX 345 13.1 DISCUSSION GUIDE 345 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 349 13.3 CUSTOMIZATION OPTIONS 351 13.4 RELATED REPORTS 352 13.5 AUTHOR DETAILS 353
圖表清單 List of Tables & Figures
TABLE 1 NOVEL TARGETED PROTEIN DEGRADERS MARKET: INCLUSIONS AND EXCLUSIONS 38 TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 50 TABLE 3 NOVEL TARGETED PROTEIN DEGRADERS MARKET: RISK ANALYSIS 52 TABLE 4 NOVEL TARGETED PROTEIN DEGRADERS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 64 TABLE 5 KEY STRATEGIC PARTNERSHIPS IN NOVEL TARGETED PROTEINS MARKET 66 TABLE 6 REIMBURSEMENT SCENARIO IN EUROPEAN COUNTRIES 76 TABLE 7 NOVEL TARGETED PROTEIN DEGRADERS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 79 TABLE 8 NUMBER OF PATENTS FILED (APPLIED/GRANTED) IN NOVEL TARGETED PROTEIN DEGRADERS MARKET, 2014–2024 80 TABLE 9 NOVEL TARGETED PROTEIN DEGRADERS MARKET: LIST OF PATENTS, 2022–2024 82 TABLE 10 NOVEL TARGETED PROTEIN DEGRADERS MARKET: PRODUCTS IN CLINICAL PIPELINE, 2025–2028 83 TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85 TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86 TABLE 15 NOVEL TARGETED PROTEIN DEGRADERS MARKET: REGULATORY SCENARIO 86 TABLE 16 NOVEL TARGETED PROTEIN DEGRADERS MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 88 TABLE 17 NOVEL TARGETED PROTEIN DEGRADERS MARKET: PORTER’S FIVE FORCES ANALYSIS 89 TABLE 18 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY DEGRADER TYPE (%) 92 TABLE 19 KEY BUYING CRITERIA, BY END USER 93 TABLE 20 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 100 TABLE 21 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 101 TABLE 22 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY REGION, 2023–2035 (USD MILLION) 101 TABLE 23 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY COUNTRY, 2023–2035 (USD MILLION) 101 TABLE 24 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY COUNTRY, 2023–2035 (USD MILLION) 102 TABLE 25 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY REGION, 2023–2035 (USD MILLION) 102 TABLE 26 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY COUNTRY, 2023–2035 (USD MILLION) 103 TABLE 27 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY REGION, 2023–2035 (USD MILLION) 103 TABLE 28 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY COUNTRY, 2023–2035 (USD MILLION) 103 TABLE 29 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MEZIGDOMIDE, BY REGION, 2023–2035 (USD MILLION) 104 TABLE 30 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MEZIGDOMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 104 TABLE 31 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MEZIGDOMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 105 TABLE 32 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MEZIGDOMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 105 TABLE 33 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MEZIGDOMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 106 TABLE 34 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MEZIGDOMIDE, BY REGION, 2023–2035 (USD MILLION) 106 TABLE 35 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MEZIGDOMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 106 TABLE 36 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR IBERDOMIDE, BY REGION, 2023–2035 (USD MILLION) 107 TABLE 37 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR IBERDOMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 107 TABLE 38 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR IBERDOMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 108 TABLE 39 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR IBERDOMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 108 TABLE 40 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR IBERDOMIDE, BY COUNTRY, 2023–2032 (USD MILLION) 109 TABLE 41 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR IBERDOMIDE, BY REGION, 2023–2035 (USD MILLION) 109 TABLE 42 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR IBERDOMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 109 TABLE 43 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 110 TABLE 44 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY REGION, 2023–2035 (USD MILLION) 110 TABLE 45 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY COUNTRY, 2023–2035 (USD MILLION) 111 TABLE 46 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY COUNTRY, 2023–2035 (USD MILLION) 111 TABLE 47 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY COUNTRY, 2023–2035 (USD MILLION) 112 TABLE 48 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY COUNTRY, 2023–2035 (USD MILLION) 112 TABLE 49 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY REGION, 2023–2035 (USD MILLION) 112 TABLE 50 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY COUNTRY, 2023–2035 (USD MILLION) 113 TABLE 51 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ELACESTRANT, BY REGION, 2023–2035(USD MILLION) 114 TABLE 52 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ELACESTRANT, BY COUNTRY, 2023–2035(USD MILLION) 114 TABLE 53 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ELACESTRANT, BY COUNTRY, 2023–2035(USD MILLION) 114 TABLE 54 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ELACESTRANT, BY COUNTRY, 2023–2035(USD MILLION) 115 TABLE 55 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ELACESTRANT, BY COUNTRY, 2023–2035(USD MILLION) 115 TABLE 56 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ELACESTRANT, BY REGION, 2023–2035(USD MILLION) 115 TABLE 57 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ELACESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 116 TABLE 58 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR GIREDESTRANT, BY REGION, 2023–2035 (USD MILLION) 116 TABLE 59 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR GIREDESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 117 TABLE 60 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR GIREDESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 117 TABLE 61 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR GIREDESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 118 TABLE 62 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR GIREDESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 118 TABLE 63 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR GIREDESTRANT, BY REGION, 2023–2035 (USD MILLION) 118 TABLE 64 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR GIREDESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 119 TABLE 65 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAMIZESTRANT, BY REGION, 2023–2035 (USD MILLION) 119 TABLE 66 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET CAMIZESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 120 TABLE 67 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAMIZESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 120 TABLE 68 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAMIZESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 121 TABLE 69 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAMIZESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 121 TABLE 70 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAMIZESTRANT, BY REGION, 2023–2035 (USD MILLION) 121 TABLE 71 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAMIZESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 122 TABLE 72 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 123 TABLE 73 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY REGION, 2023–2035 (USD MILLION) 123 TABLE 74 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY COUNTRY, 2023–2035 (USD MILLION) 124 TABLE 75 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY COUNTRY, 2023–2035 (USD MILLION) 124 TABLE 76 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY COUNTRY, 2023–2035 (USD MILLION) 125 TABLE 77 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY COUNTRY, 2023–2035 (USD MILLION) 125 TABLE 78 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY REGION, 2023–2035 (USD MILLION) 125 TABLE 79 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY COUNTRY, 2023–2035 (USD MILLION) 126 TABLE 80 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR VEPDEGESTRANT, BY REGION, 2023–2035 (USD MILLION) 126 TABLE 81 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR VEPDEGESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 127 TABLE 82 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR VEPDEGESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 127 TABLE 83 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR VEPDEGESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 127 TABLE 84 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR VEPDEGESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 128 TABLE 85 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR VEPDEGESTRANT, BY REGION, 2023–2035 (USD MILLION) 128 TABLE 86 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR VEPDEGESTRANT, BY COUNTRY, 2023–2035 (USD MILLION) 128 TABLE 87 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LUXDEGALUTAMIDE, BY REGION, 2023–2035 (USD MILLION) 129 TABLE 88 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LUXDEGALUTAMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 129 TABLE 89 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LUXDEGALUTAMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 130 TABLE 90 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LUXDEGALUTAMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 130 TABLE 91 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LUXDEGALUTAMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 131 TABLE 92 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LUXDEGALUTAMIDE, BY REGION, 2023–2035 (USD MILLION) 131 TABLE 93 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LUXDEGALUTAMIDE, BY COUNTRY, 2023–2035 (USD MILLION) 131 TABLE 94 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR BGB-16673, BY REGION, 2023–2035 (USD MILLION) 132 TABLE 95 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR BGB-16673, BY COUNTRY, 2023–2035 (USD MILLION) 132 TABLE 96 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR BGB-16673, BY COUNTRY, 2023–2035 (USD MILLION) 133 TABLE 97 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR BGB-16673, BY COUNTRY, 2023–2035 (USD MILLION) 133 TABLE 98 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR BGB-16673, BY COUNTRY, 2023–2035 (USD MILLION) 134 TABLE 99 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR BGB-16673, BY REGION, 2023–2035 (USD MILLION) 134 TABLE 100 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR BGB-16673, BY COUNTRY, 2023–2035 (USD MILLION) 134 TABLE 101 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR NX-5948, BY REGION, 2023–2035 (USD MILLION) 135 TABLE 102 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR NX-5948, BY COUNTRY, 2023–2035 (USD MILLION) 135 TABLE 103 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR NX-5948, BY COUNTRY, 2023–2035 (USD MILLION) 136 TABLE 104 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR NX-5948, BY COUNTRY, 2023–2035 (USD MILLION) 136 TABLE 105 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR NX-5948, BY COUNTRY, 2023–2035 (USD MILLION) 137 TABLE 106 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR KT‑474, BY REGION, 2023–2035 (USD MILLION) 138 TABLE 107 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR KT‑474, BY COUNTRY, 2023–2035 (USD MILLION) 138 TABLE 108 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR KT‑474, BY COUNTRY, 2023–2035 (USD MILLION) 138 TABLE 109 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR KT‑474, BY COUNTRY, 2023–2035 (USD MILLION) 139 TABLE 110 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC, BY REGION, 2023–2035 (USD MILLION) 140 TABLE 111 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC, BY COUNTRY, 2023–2035 (USD MILLION) 140 TABLE 112 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC, BY COUNTRY, 2023–2035 (USD MILLION) 140 TABLE 113 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC, BY COUNTRY, 2023–2035 (USD MILLION) 141 TABLE 114 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC, BY COUNTRY, 2023–2035 (USD MILLION) 141 TABLE 115 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC, BY REGION, 2023–2035 (USD MILLION) 141 TABLE 116 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC, BY COUNTRY, 2023–2035 (USD MILLION) 142 TABLE 117 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LYTAC/ATAC, BY REGION, 2023–2035 (USD MILLION) 143 TABLE 118 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LYTAC/ATAC, BY COUNTRY, 2023–2035 (USD MILLION) 143 TABLE 119 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LYTAC/ATAC, BY COUNTRY, 2023–2035 (USD MILLION) 143 TABLE 120 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LYTAC/ATAC, BY COUNTRY, 2023–2035 (USD MILLION) 144 TABLE 121 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR AUTAC/ATTEC, BY REGION, 2023–2035 (USD MILLION) 145 TABLE 122 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR AUTAC/ ATTEC, BY COUNTRY, 2023–2035 (USD MILLION) 145 TABLE 123 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR AUTAC /ATTEC, BY COUNTRY, 2023–2035 (USD MILLION) 145 TABLE 124 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR AUTAC /ATTEC, BY COUNTRY, 2023–2035 (USD MILLION) 146 TABLE 125 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 148 TABLE 126 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ONCOLOGY, BY REGION, 2023–2035 (USD MILLION) 149 TABLE 127 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2035 (USD MILLION) 149 TABLE 128 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2028 (USD MILLION) 150 TABLE 129 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2028 (USD MILLION) 150 TABLE 130 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2035 (USD MILLION) 151 TABLE 131 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ONCOLOGY, BY REGION, 2023–2035 (USD MILLION) 151 TABLE 132 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2035 (USD MILLION) 151 TABLE 133 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INFLAMMATORY DISEASES, BY REGION, 2023–2035 (USD MILLION) 152 TABLE 134 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 153 TABLE 135 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2023–2028 (USD MILLION) 153 TABLE 136 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 154 TABLE 137 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR OTHER DISEASES, BY REGION, 2023–2035 (USD MILLION) 155 TABLE 138 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 155 TABLE 139 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2028 (USD MILLION) 155 TABLE 140 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 156 TABLE 141 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 158 TABLE 142 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 158 TABLE 143 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY REGION, 2023–2035 (USD MILLION) 159 TABLE 144 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2023–2035 (USD MILLION) 159 TABLE 145 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2023–2028 (USD MILLION) 160 TABLE 146 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2023–2028 (USD MILLION) 160 TABLE 147 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2023–2035 (USD MILLION) 161 TABLE 148 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY REGION, 2023–2035 (USD MILLION) 161 TABLE 149 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2023–2035 (USD MILLION) 161 TABLE 150 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR TABLETS, BY REGION, 2023–2035 (USD MILLION) 162 TABLE 151 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR TABLETS, BY COUNTRY, 2023–2035 (USD MILLION) 162 TABLE 152 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR TABLETS, BY COUNTRY, 2023–2028 (USD MILLION) 163 TABLE 153 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR TABLETS, BY COUNTRY, 2023–2035 (USD MILLION) 163 TABLE 154 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR TABLETS, BY COUNTRY, 2023–2035 (USD MILLION) 164 TABLE 155 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR TABLETS, BY REGION, 2023–2035 (USD MILLION) 164 TABLE 156 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR TABLETS, BY COUNTRY, 2023–2035 (USD MILLION) 164 TABLE 157 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES, BY REGION, 2023–2035 (USD MILLION) 165 TABLE 158 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES, BY COUNTRY, 2023–2035 (USD MILLION) 165 TABLE 159 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES, BY COUNTRY, 2023–2028 (USD MILLION) 166 TABLE 160 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES, BY COUNTRY, 2023–2035 (USD MILLION) 166 TABLE 161 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES, BY COUNTRY, 2023–2035 (USD MILLION) 167 TABLE 162 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES, BY REGION, 2023–2035 (USD MILLION) 167 TABLE 163 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES, BY COUNTRY, 2023–2035 (USD MILLION) 167 TABLE 164 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INJECTIONS, BY REGION, 2023–2035 (USD MILLION) 168 TABLE 165 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INJECTIONS, BY COUNTRY, 2023–2035 (USD MILLION) 169 TABLE 166 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INJECTIONS, BY COUNTRY, 2023–2028 (USD MILLION) 169 TABLE 167 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INJECTIONS, BY COUNTRY, 2023–2035 (USD MILLION) 170 TABLE 168 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 172 TABLE 169 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2023–2035 (USD MILLION) 173 TABLE 170 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2035 (USD MILLION) 173 TABLE 171 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2028 (USD MILLION) 174 TABLE 172 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2028 (USD MILLION) 174 TABLE 173 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2035 (USD MILLION) 175 TABLE 174 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2023–2035 (USD MILLION) 175 TABLE 175 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2035 (USD MILLION) 175 TABLE 176 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2035 (USD MILLION) 176 TABLE 177 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2035 (USD MILLION) 176 TABLE 178 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2028 (USD MILLION) 177 TABLE 179 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2035 (USD MILLION) 177 TABLE 180 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2035 (USD MILLION) 178 TABLE 181 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2035 (USD MILLION) 178 TABLE 182 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2035 (USD MILLION) 178 TABLE 183 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOME CARE SETTINGS, BY REGION, 2023–2035 (USD MILLION) 179 TABLE 184 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2035 (USD MILLION) 179 TABLE 185 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2028 (USD MILLION) 180 TABLE 186 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2035 (USD MILLION) 180 TABLE 187 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2035 (USD MILLION) 181 TABLE 188 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOME CARE SETTINGS, BY REGION, 2023–2035 (USD MILLION) 181 TABLE 189 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2035 (USD MILLION) 181 TABLE 190 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY REGION, 2023–2035 (USD MILLION) 183 TABLE 191 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 184 TABLE 192 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 186 TABLE 193 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 186 TABLE 194 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 186 TABLE 195 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 187 TABLE 196 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 187 TABLE 197 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 187 TABLE 198 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 188 TABLE 199 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 188 TABLE 200 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 188 TABLE 201 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 189 TABLE 202 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 190 TABLE 203 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 190 TABLE 204 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 190 TABLE 205 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 191 TABLE 206 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 191 TABLE 207 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 191 TABLE 208 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 192 TABLE 209 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 193 TABLE 210 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 193 TABLE 211 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 193 TABLE 212 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 194 TABLE 213 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 194 TABLE 214 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 194 TABLE 215 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 195 TABLE 216 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 195 TABLE 217 EUROPE: KEY MACROECONOMIC INDICATORS 196 TABLE 218 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 197 TABLE 219 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 197 TABLE 220 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 198 TABLE 221 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 198 TABLE 222 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 198 TABLE 223 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 199 TABLE 224 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 199 TABLE 225 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 199 TABLE 226 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 200 TABLE 227 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 201 TABLE 228 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 201 TABLE 229 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 201 TABLE 230 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 202 TABLE 231 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 202 TABLE 232 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 202 TABLE 233 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 203 TABLE 234 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 203 TABLE 235 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 204 TABLE 236 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 204 TABLE 237 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 204 TABLE 238 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 205 TABLE 239 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 205 TABLE 240 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 205 TABLE 241 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 206 TABLE 242 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 206 TABLE 243 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 207 TABLE 244 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 207 TABLE 245 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 207 TABLE 246 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 208 TABLE 247 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 208 TABLE 248 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 208 TABLE 249 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 209 TABLE 250 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 209 TABLE 251 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 210 TABLE 252 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 210 TABLE 253 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 211 TABLE 254 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 211 TABLE 255 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 211 TABLE 256 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 212 TABLE 257 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 212 TABLE 258 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 212 TABLE 259 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 213 TABLE 260 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 213 TABLE 261 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 214 TABLE 262 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 214 TABLE 263 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 214 TABLE 264 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 215 TABLE 265 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 215 TABLE 266 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 215 TABLE 267 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 216 TABLE 268 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 216 TABLE 269 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 217 TABLE 270 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 217 TABLE 271 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 217 TABLE 272 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 218 TABLE 273 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 218 TABLE 274 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 218 TABLE 275 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 220 TABLE 276 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 221 TABLE 277 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 221 TABLE 278 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 222 TABLE 279 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 222 TABLE 280 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 222 TABLE 281 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 223 TABLE 282 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 223 TABLE 283 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 223 TABLE 284 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 224 TABLE 285 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 225 TABLE 286 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 225 TABLE 287 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 225 TABLE 288 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 226 TABLE 289 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 226 TABLE 290 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 226 TABLE 291 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 227 TABLE 292 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 227 TABLE 293 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 228 TABLE 294 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 228 TABLE 295 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 228 TABLE 296 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 229 TABLE 297 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 229 TABLE 298 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 229 TABLE 299 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 230 TABLE 300 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 230 TABLE 301 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 231 TABLE 302 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 231 TABLE 303 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 231 TABLE 304 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 232 TABLE 305 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 232 TABLE 306 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 232 TABLE 307 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 233 TABLE 308 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 233 TABLE 309 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 234 TABLE 310 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 234 TABLE 311 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 234 TABLE 312 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 235 TABLE 313 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 235 TABLE 314 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 235 TABLE 315 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 236 TABLE 316 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 236 TABLE 317 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 237 TABLE 318 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 237 TABLE 319 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 237 TABLE 320 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 238 TABLE 321 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 238 TABLE 322 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 238 TABLE 323 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 239 TABLE 324 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 239 TABLE 325 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 240 TABLE 326 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 240 TABLE 327 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 241 TABLE 328 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 241 TABLE 329 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 241 TABLE 330 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 242 TABLE 331 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 242 TABLE 332 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 242 TABLE 333 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 244 TABLE 334 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 244 TABLE 335 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 245 TABLE 336 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 245 TABLE 337 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 245 TABLE 338 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 246 TABLE 339 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 246 TABLE 340 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 246 TABLE 341 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 247 TABLE 342 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 247 TABLE 343 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 248 TABLE 344 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 248 TABLE 345 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 248 TABLE 346 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 249 TABLE 347 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 249 TABLE 348 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 249 TABLE 349 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 250 TABLE 350 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 250 TABLE 351 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 251 TABLE 352 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 251 TABLE 353 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 252 TABLE 354 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 252 TABLE 355 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 252 TABLE 356 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 253 TABLE 357 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 253 TABLE 358 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 253 TABLE 359 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 254 TABLE 360 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 254 TABLE 361 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 255 TABLE 362 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 255 TABLE 363 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 255 TABLE 364 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 256 TABLE 365 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 256 TABLE 366 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 256 TABLE 367 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS 258 TABLE 368 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY REGION, 2023–2035 (USD MILLION) 258 TABLE 369 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 259 TABLE 370 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 259 TABLE 371 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 259 TABLE 372 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 260 TABLE 373 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 260 TABLE 374 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 260 TABLE 375 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 261 TABLE 376 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 261 TABLE 377 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 262 TABLE 378 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 262 TABLE 379 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 262 TABLE 380 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 263 TABLE 381 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 263 TABLE 382 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 263 TABLE 383 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 264 TABLE 384 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 264 TABLE 385 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 264 TABLE 386 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 265 TABLE 387 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 265 TABLE 388 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 266 TABLE 389 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 266 TABLE 390 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 266 TABLE 391 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 267 TABLE 392 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 267 TABLE 393 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 267 TABLE 394 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 268 TABLE 395 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 268 TABLE 396 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 269 TABLE 397 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 269 TABLE 398 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 269 TABLE 399 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 270 TABLE 400 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 270 TABLE 401 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 270 TABLE 402 REST OF GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 271 TABLE 403 REST OF GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 271 TABLE 404 REST OF GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 272 TABLE 405 REST OF GCC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 272 TABLE 406 REST OF GCC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 272 TABLE 407 REST OF GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 273 TABLE 408 REST OF GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 273 TABLE 409 REST OF GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 273 TABLE 410 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023–2035 (USD MILLION) 274 TABLE 411 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023–2035 (USD MILLION) 275 TABLE 412 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023–2035 (USD MILLION) 275 TABLE 413 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023–2035 (USD MILLION) 275 TABLE 414 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023–2035 (USD MILLION) 276 TABLE 415 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023–2035 (USD MILLION) 276 TABLE 416 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023–2035 (USD MILLION) 276 TABLE 417 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023–2035 (USD MILLION) 277 TABLE 418 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN NOVEL TARGETED PROTEIN DEGRADERS MARKET, 2023–2025 278 TABLE 419 NOVEL TARGETED PROTEIN DEGRADERS MARKET: DEGREE OF COMPETITION 282 TABLE 420 NOVEL TARGETED PROTEIN DEGRADERS MARKET: REGION FOOTPRINT 288 TABLE 421 NOVEL TARGETED PROTEIN DEGRADERS MARKET: DEGRADER TYPE FOOTPRINT 289 TABLE 422 NOVEL TARGETED PROTEIN DEGRADERS MARKET: THERAPEUTIC INDICATION FOOTPRINT 290 TABLE 423 NOVEL TARGETED PROTEIN DEGRADERS MARKET: FORMULATION FOOTPRINT 291 TABLE 424 NOVEL TARGETED PROTEIN DEGRADERS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 294 TABLE 425 NOVEL TARGETED PROTEIN DEGRADERS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, 2024 295 TABLE 426 NOVEL TARGETED PROTEIN DEGRADERS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025 296 TABLE 427 NOVEL TARGETED PROTEIN DEGRADERS MARKET: DEALS, JANUARY 2022–AUGUST 2025 297 TABLE 428 NOVEL TARGETED PROTEIN DEGRADERS MARKET: EXPANSIONS, JANUARY 2022– AUGUST 2025 298 TABLE 429 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW 299 TABLE 430 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED 300 TABLE 431 BRISTOL MYERS SQUIBB COMPANY: DEALS, JANUARY 2022–JULY 2025 301 TABLE 432 BRISTOL-MYERS SQUIBB COMPANY: EXPANSIONS, JANUARY 2022–JULY 2025 302 TABLE 433 THE MENARINI GROUP: COMPANY OVERVIEW 303 TABLE 434 THE MENARINI GROUP: PRODUCTS OFFERED 304 TABLE 435 THE MENARINI GROUP: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 305 TABLE 436 ARVINAS: COMPANY OVERVIEW 307 TABLE 437 ARVINAS: PRODUCTS OFFERED 308 TABLE 438 ARVINAS: DEALS, JANUARY 2022–JULY 2025 308 TABLE 439 BEONE MEDICINES: COMPANY OVERVIEW 310 TABLE 440 BEONE MEDICINES: PRODUCTS OFFERED 311 TABLE 441 BEONE MEDICINES: DEALS, JANUARY 2022–JULY 2025 311 TABLE 442 NURIX THERAPEUTICS, INC.: COMPANY OVERVIEW 312 TABLE 443 NURIX THERAPEUTICS, INC.: PRODUCTS OFFERED 313 TABLE 444 NURIX THERAPEUTICS, INC.: DEALS, JANUARY 2022–JULY 2025 313 TABLE 445 KYMERA THERAPEUTICS, INC.: COMPANY OVERVIEW 314 TABLE 446 KYMERA THERAPEUTICS, INC.: PRODUCTS OFFERED 315 TABLE 447 KYMERA THERAPEUTICS, INC.: DEALS, JANUARY 2022–JULY 2025 315 TABLE 448 C4 THERAPEUTICS, INC.: COMPANY OVERVIEW 316 TABLE 449 C4 THERAPEUTICS, INC.: PRODUCTS OFFERED 317 TABLE 450 C4 THERAPEUTICS, INC.: DEALS, JANUARY 2022–JULY 2025 317 TABLE 451 ASTRAZENECA: COMPANY OVERVIEW 318 TABLE 452 ASTRAZENECA: PRODUCTS OFFERED 319 TABLE 453 ASTRAZENECA: DEALS, JANUARY 2022–JULY 2025 320 TABLE 454 ASTRAZENECA: EXPANSIONS, JANUARY 2022–JULY 2025 320 TABLE 455 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 321 TABLE 456 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 322 TABLE 457 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2022–JULY 2025 323 TABLE 458 BAYER AG: COMPANY OVERVIEW 324 TABLE 459 BAYER AG: PRODUCTS OFFERED 325 TABLE 460 BAYER AG: DEALS, JANUARY 2022–JULY 2025 326 TABLE 461 CAPTOR THERAPEUTICS: COMPANY OVERVIEW 327 TABLE 462 CAPTOR THERAPEUTICS: PRODUCTS OFFERED 327 TABLE 463 CAPTOR THERAPEUTICS: DEALS, JANUARY 2022–JULY 2025 328 TABLE 464 RANOK THERAPEUTICS CO. LTD.: COMPANY OVERVIEW 329 TABLE 465 RANOK THERAPEUTICS CO. LTD.: PRODUCTS OFFERED 329 TABLE 466 RANOK THERAPEUTICS CO. LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 329 TABLE 467 PFIZER INC.: COMPANY OVERVIEW 330 TABLE 468 PFIZER INC.: PRODUCTS OFFERED 331 TABLE 469 PFIZER INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 332 TABLE 470 NOVARTIS AG: COMPANY OVERVIEW 333 TABLE 471 NOVARTIS AG: PRODUCTS OFFERED 334 TABLE 472 NOVARTIS AG: DEALS, JANUARY 2022–JULY 2025 335 TABLE 473 FOGHORN THERAPEUTICS: COMPANY OVERVIEW 336 TABLE 474 FOGHORN THERAPEUTICS: PRODUCTS OFFERED 337 TABLE 475 FOGHORN THERAPEUTICS: DEALS, JANUARY 2022–JULY 2025 337 TABLE 476 MONTE ROSA THERAPEUTICS: COMPANY OVERVIEW 338 TABLE 477 BIOTHERYX, INC.: COMPANY OVERVIEW 339 TABLE 478 CULLGEN: COMPANY OVERVIEW 340 TABLE 479 NEOMORPH: COMPANY OVERVIEW 340 TABLE 480 LYCIA THERAPEUTICS: COMPANY OVERVIEW 341 TABLE 481 PHOTYS THERAPEUTICS: COMPANY OVERVIEW 341 TABLE 482 PLEXIUM, INC.: COMPANY OVERVIEW 342 TABLE 483 SEED THERAPEUTICS, INC.: COMPANY OVERVIEW 343 TABLE 484 AVILAR THERAPEUTICS, INC.: COMPANY OVERVIEW 344 TABLE 485 AUTOMERA: COMPANY OVERVIEW 344 FIGURE 1 NOVEL TARGETED PROTEIN DEGRADERS MARKET SEGMENTATION AND REGIONAL SCOPE 37 FIGURE 2 NOVEL TARGETED PROTEIN DEGRADERS MARKET: YEARS CONSIDERED 38 FIGURE 3 NOVEL TARGETED PROTEIN DEGRADERS MARKET: RESEARCH DESIGN 40 FIGURE 4 NOVEL TARGETED PROTEIN DEGRADERS MARKET: KEY DATA FROM SECONDARY SOURCES 42 FIGURE 5 NOVEL TARGETED PROTEIN DEGRADERS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 43 FIGURE 6 NOVEL TARGETED PROTEIN DEGRADERS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 44 FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH, 2030 45 FIGURE 8 REVENUE SHARE ANALYSIS OF MENARINI GROUP, 2024 45 FIGURE 9 NOVEL TARGETED PROTEIN DEGRADERS MARKET SIZE VALIDATION FROM PRIMARY SOURCES 47 FIGURE 10 NOVEL TARGETED PROTEIN DEGRADERS MARKET: TOP-DOWN APPROACH 48 FIGURE 11 NOVEL TARGETED PROTEIN DEGRADERS MARKET: CAGR PROJECTIONS 49 FIGURE 12 NOVEL TARGETED PROTEIN DEGRADERS MARKET: DATA TRIANGULATION 51 FIGURE 13 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2030 VS. 2035 (USD MILLION) 55 FIGURE 14 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2030 VS. 2035 (USD MILLION) 56 FIGURE 15 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2030 VS. 2035 (USD MILLION) 56 FIGURE 16 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2030 VS. 2035 (USD MILLION) 57 FIGURE 17 GEOGRAPHICAL SNAPSHOT OF NOVEL TARGETED PROTEIN DEGRADERS MARKET 58 FIGURE 18 INCREASING RESEARCH INVESTMENTS AND RISING DEMAND FOR TARGETED TREATMENT TO DRIVE MARKET 59 FIGURE 19 SERDS SEGMENT AND US TO LEAD NORTH AMERICAN MARKET IN 2030 60 FIGURE 20 AUSTRALIA TO HAVE HIGHEST GROWTH DURING FORECAST PERIOD 61 FIGURE 21 EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 62 FIGURE 22 NOVEL TARGETED PROTEIN DEGRADERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 63 FIGURE 23 NEW REVENUE POCKETS FOR PLAYERS IN NOVEL TARGETED PROTEIN DEGRADERS MARKET 74 FIGURE 24 NOVEL TARGETED PROTEIN DEGRADERS MARKET: VALUE CHAIN ANALYSIS 77 FIGURE 25 NOVEL TARGETED PROTEIN DEGRADERS MARKET: ECOSYSTEM ANALYSIS 79 FIGURE 26 NOVEL TARGETED PROTEIN DEGRADERS MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024 81 FIGURE 27 NOVEL TARGETED PROTEIN DEGRADERS MARKET: PORTER’S FIVE FORCES ANALYSIS 89 FIGURE 28 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY DEGRADER TYPE 91 FIGURE 29 KEY BUYING CRITERIA, BY END USER 93 FIGURE 30 NOVEL TARGETED PROTEIN DEGRADERS MARKET: INVESTMENT AND FUNDING SCENARIO, 2021–2024 94 FIGURE 31 NOVEL TARGETED PROTEIN DEGRADERS MARKET: IMPACT OF AI/GEN AI 95 FIGURE 32 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET SNAPSHOT 185 FIGURE 33 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET SNAPSHOT 220 FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS, 2028–2030 (USD MILLION) 280 FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN NOVEL TARGETED PROTEIN DEGRADERS MARKET, 2030 281 FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 283 FIGURE 37 EV/EBITDA OF KEY VENDORS 283 FIGURE 38 NOVEL TARGETED PROTEIN DEGRADERS MARKET: BRAND/PRODUCT COMPARISON 284 FIGURE 39 NOVEL TARGETED PROTEIN DEGRADERS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 286 FIGURE 40 NOVEL TARGETED PROTEIN DEGRADERS MARKET: COMPANY FOOTPRINT 287 FIGURE 41 NOVEL TARGETED PROTEIN DEGRADERS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 293 FIGURE 42 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2024) 300 FIGURE 43 THE MENARINI GROUP: COMPANY SNAPSHOT (2024) 304 FIGURE 44 ARVINAS: COMPANY SNAPSHOT (2024) 307 FIGURE 45 BEONE MEDICINES: COMPANY SNAPSHOT (2024) 310 FIGURE 46 NURIX THERAPEUTICS, INC.: COMPANY SNAPSHOT (2024) 312 FIGURE 47 KYMERA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2024) 314 FIGURE 48 C4 THERAPEUTICS, INC.: COMPANY SNAPSHOT (2024) 316 FIGURE 49 ASTRAZENECA: COMPANY SNAPSHOT (2024) 319 FIGURE 50 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024) 322 FIGURE 51 BAYER AG: COMPANY SNAPSHOT (2024) 325 FIGURE 52 PFIZER INC.: COMPANY SNAPSHOT (2024) 331 FIGURE 53 NOVARTIS AG: COMPANY SNAPSHOT (2024) 334 FIGURE 54 FORGHORN THERAPEUTICS: COMPANY SNAPSHOT (2024) 336

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們